MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE

MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload.

MarketBeat • Jul 24, 2026

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration's (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease.

Benzinga • Jul 24, 2026

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript

Seeking Alpha • Jul 24, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema

GlobeNewsWire • Jul 24, 2026

MannKind Announces $50 Million Private Placement

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Jul 24, 2026

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk

The transactions involved 76,880 shares with a total value of about $313,000, based on a weighted average execution price of $4.07 per share. The disposition represented 9% of direct common stock holdings, which included shares delivered upon the recent vesting of performance-based awards.

The Motley Fool • Jul 20, 2026

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk

This filing reported an insider's total disposition of 65,808 shares for an estimated value of $269,000 based on the July 15, 2026 market close. The transaction represented 6% of the insider's total direct common stock holdings.

The Motley Fool • Jul 20, 2026

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million

David Thomson disposed of 123,000 shares at $4.08 per share, representing a total transaction value of about $500,000. The activity resulted in a 13% decrease in direct common stock holdings, which included shares recently acquired through the exercise of derivative securities.

The Motley Fool • Jul 20, 2026

What This MannKind Filing Reveals About Three Years of Underperformance

This MannKind insider filing details the disposition of 46,795 shares. The transaction reduced the insider's direct equity holdings by 9%.

The Motley Fool • Jul 20, 2026

Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?

The disposition involved ~363,000 shares valued at ~$1.5 million as of the July 15, 2026 transaction date. The activity represents 13% of the executive's direct equity holdings in the company.

The Motley Fool • Jul 20, 2026